Folinic Acid Administration Following MTX as Prophylaxis for GVHD in Allogeneic HSCT Centres in Australia and New Zealand

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2008.197
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Folinic Acid Administration Following MTX as Prophylaxis for GVHD

Bone Marrow Transplantation
TransplantationHematology
2009English

New Strategies in GVHD Prophylaxis

Bone Marrow Transplantation
TransplantationHematology
2000English

Decreased Insulin Secretion in Patients Receiving Tacrolimus as GVHD Prophylaxis After Allogeneic Hematopoietic SCT

Bone Marrow Transplantation
TransplantationHematology
2009English

MTX or Mycophenolate Mofetil With CsA as GVHD Prophylaxis After Reduced-Intensity Conditioning PBSCT From HLA-identical Siblings

Bone Marrow Transplantation
TransplantationHematology
2010English

Australia and New Zealand

World Statistics Pocketbook 2017
2017English

Australia and New Zealand

2019English

Australia and New Zealand

Public Health Economics
1956English

Psy124 - Cost of Allogeneic HSCT Complications in Brazil: A Deterministic Linkage Approach Focusing on Patients With GVHD

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pharmaceutical Policies in Australia and New Zealand

Journal of Pharmaceutical Policy and Practice
ToxicologyPharmaceuticsPharmacologyHealth Policy
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy